Diabetes is a complex chronic illness that poses significant healthcare burdens in terms of cost and management. Persons with diabetes are at risk for significant cardiovascular and renal complications, however, insulins and other traditional therapies, while beneficial for attaining glycemic targets, have lacked additional benefits for cardiovascular or renal protection. Newer therapies emerging within the last decade have demonstrated cardiovascular, renal, and weight loss benefits, and have allowed for down-titration and sometimes elimination of older therapies with often deleterious side effects.
This session provides an initial overview of existing guidance for pharmacotherapy in T2DM; will compare and contrast existing guidance with newly released ADA 2023 Standards of Care; and will conclude with an interactive case-based format providing the audience opportunity to discuss T2DM management scenarios relevant to daily practice.
Objectives:
Statement of Accreditation
The Texas Osteopathic Medical Association (TOMA) is accredited by the American Osteopathic Association to provide osteopathic continuing medical education for physicians. TOMA designates is program for a maximum of 1 AOA Category 1-A credits and will report CME credits commensurate with the extent of the physician’s participation in this activity.
Grievance Policy
All grievances may be directed to TOMA's Executive Director at toma@txosteo.org. All grievances will receive an initial response within 30 days of receipt. If the participant does not receive a satisfactory response, they can submit a complaint to the Bureau of Osteopathic Education of the AOA at 142 East Ontario Street, Chicago, IL 60611.